Compare GSK plc (GSK) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Kraft Heinz Co — how do they compare? GSK plc trades at $52.39 (market cap $101.34B), while Kraft Heinz Co trades at $25.91 (market cap $30.18B). The key difference: GSK plc is far larger — about 3.4× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (6.29%). Which is the better fit depends on your goals.
| GSK | KHC | |
|---|---|---|
Market Cap | $101.34B | $30.18B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $28.94 |
52-Week Low | $36.20 | $21.21 |
Enterprise Value | $121.95B | $47.22B |
Dividend Yield | 3.49% | 6.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Kraft Heinz (KHC) trades at $25.08, down 0.59% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings expectations for three consecutive quarters, though it reported a net loss of $5.85B in 2025. Valuation metrics show a low P/B ratio of 0.72, while the company maintains strong operating cash flow of $4.46B and recently announced a global restructuring to accelerate growth.
KHC presents a mixed investment case with attractive valuation and dividend yield (6.4%) offset by profitability challenges. The stock trades above analyst consensus target of $23.20, suggesting limited near-term upside. Key risks include persistent negative margins and high debt levels, while potential catalysts include successful restructuring execution and margin improvement in upcoming quarters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
